MedDataX Logo

Geodon in Weight Loss Study for Bipolar Disorders

NCT00472641 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-05-09

Study results available
· View outcomes & findings →

Summary

This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder. There will be approximately 25 patients enrolled in this study.

Conditions

  • Bipolar Disorder

Interventions

DRUG

Ziprasidone/Geodon

Ziprasidone/Geodon

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Stanford University

    lead OTHER

Principal Investigators

  • Terence Arthur Ketter · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00472641 on ClinicalTrials.gov